Who Paid My Doc Search
Menu
Organisation paid for research Program year 2023 Source: CMS Open Payments

Central Dermatology

Neither a doctor nor a teaching hospital

Research payments

$152,291

56 payments

Through program year 2023, Central Dermatology is reported as receiving $152,291 in research payments, across 56 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $24,357 2
2022 Research $10,692 4
2021 Research $38,360 13
2020 Research $66,024 32
2019 Research $12,858 5

Breakdown

Who paid Research payments · program years 2019–2023
  1. AbbVie, Inc. $100,877 38 payments
  2. Ucb SA $34,419 4 payments
  3. Celgene Corporation $10,896 3 payments
  4. Novartis Pharmaceuticals Corporation $4,408 7 payments
  5. Merck Sharp & Dohme Corporation $994 1 payment
  6. Amgen Inc. $627 2 payments
  7. Pfizer Inc. $70 1 payment
Studies the money was for Research payments · program years 2019–2023
  1. M15-997 $49,343 19 payments
  2. A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) $33,285 7 payments
  3. A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis. $28,610 2 payments
  4. A Phase 3, Multi-Center, Randomized, Place-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004 in subjects with Moderate to Sever Plaque Psoriasis of the Scap) (CC-10004-SPSO-001) $9,676 1 payment
  5. M16-005 $9,151 5 payments
  6. A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis $5,809 2 payments
  7. M19-164 $4,479 2 payments
  8. A Randomized Double Blind Placebo Controlled Parallel Group Dose Ranging Study to Determine the Efficacy and Safety of Oral Zpl389a 3 MG 10 MG 30 MG and 50 MG Capsules Administered for 16 Weeks in Subjects With Moderate to Severe Atopic Dermatitis $3,612 5 payments
  9. A Phase 3b, Multicenter, Interventional, Open-label Study of Adult Subjects with Moderate to Severe Plaque Psoriasis who have a Suboptimal Response to Secukinumab or Ixekizumab and are Switched to Risankizumab $3,514 3 payments
  10. A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety,Tolerability of Subcutaneous SCH 900222,MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis Protocol No. MK-3222-010 $994 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record